Over the Counter Estrogen Replacement: What You Can Actually Buy Without a Prescription

The HRT Index Editorial TeamIndependent women's health research

Last reviewed:September 1, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: September 1, 2026 · Last verified: September 1, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Before you buy an OTC estrogen product

Separate supplements, moisturizers, unapproved hormone products, and prescription estrogen before you spend money or change treatment.

Match your symptoms to the right care path

There is no FDA-approved over the counter estrogen replacement sold in the United States. Every FDA-approved estrogen medicine—pill, patch, gel, spray, vaginal cream, tablet, insert, or ring—requires a prescription. Products sold without one fall into different categories: unapproved hormone drugs, supplements that contain no estrogen drug, and nonhormonal moisturizers or lubricants. The right next step depends on your symptom.

That's the short answer. Here's the part almost nobody tells you.

We opened four current federal drug-label records for topical estrogen products that their own labelers registered as over-the-counter human drugs. All four are filed under the marketing category unapproved drug other. On three of the four, the strength on the label does not reconcile with the structured strength in the same federal record. One record contains three conflicting amounts. Another warning names a hormone that is not listed as an ingredient.

So the real problem with over the counter estrogen is not that it is automatically weak. It is that the label may not let you establish the amount—and we can show you exactly where that breaks down, product by product, with the record numbers so you can check us.

Then we priced both roads. A dated basket containing one menopause supplement, one no-prescription Bi-EST cream, and one vaginal moisturizer totaled $796.02 for a year before tax or shipping. A modeled first year of generic FDA-approved vaginal estradiol, using a labeled regimen and a one-time telehealth visit priced from $34, came to about $132 to $202. That prescription estimate applies to local vaginal estrogen, not systemic treatment for hot flashes, and the provider must decide that it is appropriate.

The no-prescription stack can be the expensive one. Let's walk through it.

Best for / not for you

This page is for a U.S. reader trying to identify or replace something sold as OTC estrogen, especially for menopause-related symptoms. It is not a personal safety assessment, cancer-care decision, fertility guide, or substitute for an examination when bleeding, unexplained pain, sores, a lump, or another red-flag symptom is present.

This page is for you if…	This page is not for you if…
You want estrogen and are trying to avoid the cost, wait, or conversation	You already have a prescription and want to compare brands → see our FDA-approved HRT medication list
You are holding a jar labeled "estrogen cream" and want to know what it actually is	You want to know whether hormone therapy is safe for you → that requires a clinician who knows your history
You want the cheapest legitimate route, with dated prices and the assumptions shown	You have had bleeding after menopause, unexplained pelvic pain, a new lump or sore, or another symptom that needs an examination
Your main symptom is vaginal dryness or pain with sex and you want to know what can help now	You are looking for gender-affirming hormone care or fertility treatment—different intents, different clinical paths

What we actually verified

We opened these ourselves on September 1, 2026: 21 CFR 310.530, the federal rule for topical OTC hormone products; four current DailyMed drug-label records, including the displayed label and structured strength fields; FDA 510(k) records for named vaginal moisturizers; the randomized trial in JAMA Internal Medicine comparing a 10-microgram vaginal estradiol tablet, moisturizer, and placebo; The Menopause Society's 2023 nonhormone therapy position statement; FDA's current prescription-to-nonprescription switch list; FDA's February 2026 hormone-therapy label update; FDA's April 2026 meeting on nonprescription access; and the UK regulator's reclassification of Gina 10-microgram vaginal tablets.

What we could not verify: the true hormone content of any of the four no-prescription creams—we found no public independent assay for these four current products, and we did not test them; a single national cash price for prescription estradiol, because coupons vary by pharmacy and ZIP code; a published standalone price for Hers' estradiol vaginal cream; or whether FDA will approve a nonprescription vaginal estrogen product, and when.

Prices in this article are dated snapshots, not quotes. Retail, coupon, visit, and subscription prices can change. Re-check the final price before you pay.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

The right online HRT provider isn't the same for every woman—it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider—and to flag when online care isn't the right starting point—before your first consult.

Can you buy over the counter estrogen replacement in the United States?

No. Every FDA-approved estrogen medicine in the United States requires a prescription. As of September 1, 2026, no estrogen product appears on FDA's current Prescription to Nonprescription Switch List. Products sold without a prescription that use estrogen language may be supplements, nonhormonal products, or unapproved drugs—not FDA-approved OTC estrogen.

The word "OTC" describes how something is sold. It does not tell you whether FDA approved it, whether a hormone is present, or whether the product was shown to work. Completely different legal categories appear beside one another in search results and marketplace listings, often using the same words on the front of the package.

The federal rule is unusually direct. Under 21 CFR 310.530, FDA found a lack of adequate data establishing effectiveness for topical OTC use of estrogens, progesterone, pregnenolone, and pregnenolone acetate. The rule says that, except for hydrocortisone products covered elsewhere, an OTC product promoted as a topical hormone drug needs an approved drug application; without one, it is also misbranded.

One more thing is worth clearing up because it created real hope this year. In November 2025, FDA began a process to revise menopausal hormone-therapy warnings. On February 12, 2026, FDA approved label changes for six products, removing risk statements related to cardiovascular disease, breast cancer, and probable dementia from the boxed warning. The first six were Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.

That was a change to the warnings. It was not a change to access. Every one of those products remains prescription-only.

The search behind this page is rarely academic. It is usually some version of: I need relief, I do not want to wait months, and I do not want to waste another $50 on a product that cannot do what I need. That urgency is reasonable. It just makes the category easier to exploit.

What are stores actually selling as "OTC estrogen"?

Products marketed with over-the-counter estrogen language sit in different legal categories: unapproved hormone drugs, dietary supplements, nonhormonal moisturizers or lubricants, FDA-approved prescription estrogen, and compounded prescription hormones. They are not weaker and stronger versions of one product. Each has different evidence, labeling rules, quality controls, and next steps.

We built this map because the word estrogen on the front of a package hides more than it reveals. Five doors. They are not degrees of the same thing.

The five doors of the "estrogen" aisle

Door	What is behind it	Governing path	What FDA reviews before sale	What the label means in practice	Examples
1. No-prescription hormone creams	Topical products declaring estriol, estradiol, progesterone, or pregnenolone and sold without a prescription	21 CFR 310.530	No approved application was identified for the four products we audited	FDA's rule treats hormone language as an implied drug claim and requires an approved application for this OTC use; the four records are marked unapproved drug other	BiEST 5.0 Estrogen Cream; Estriol 5.0 Cream; Estriol 5000 mcg; Beilloso Women Estriol
2. Dietary supplements	Black cohosh, soy isoflavones, S-equol, rhapontic rhubarb, wild yam, oral DHEA, and mixed "estrogen support" formulas	Dietary-supplement law	No FDA premarket approval for effectiveness; the company is responsible for safety and substantiation	A supplement may make qualifying structure/function claims with the required disclaimer, but it may not legally claim to diagnose, treat, cure, or prevent disease	Remifemin; Estroven Complete; Equelle; wild yam capsules
3. Nonhormonal vaginal moisturizers and lubricants	Water-, silicone-, polycarbophil-, or hyaluronic-acid products	Regulatory status varies; some named products have Class II 510(k) clearances under 21 CFR 884.5300/product code NUC	For a cleared device, FDA reviews substantial equivalence—not drug effectiveness	These products add moisture or reduce friction. They do not become estrogen because they sit in the same aisle	Replens; Revaree Plus; Vagisan; personal lubricants
4. FDA-approved prescription estrogen	Pills, patches, gels, sprays, vaginal creams, tablets, inserts, and rings	NDA or ANDA under section 505 of the FD&C Act	Safety, effectiveness, quality, manufacturing, and labeling are reviewed under the applicable application	The drug has a defined formulation, labeled uses, prescribing information, and pharmacy dispensing	Generic estradiol cream; Vagifem/Yuvafem; Imvexxy; Estring; Climara; Divigel; Premarin
5. Compounded prescription hormones	Patient-specific creams, capsules, or troches prepared by a compounding pharmacy	Usually FD&C Act §503A for traditional patient-specific compounding	FDA does not approve compounded drugs or review them for safety, effectiveness, or quality before use	These are prescription products, not OTC products, and they are not FDA-approved	Compounded Bi-EST or Tri-EST preparations

Two distinctions carry the rest of this page.

Door 1 and Door 5 are both not FDA-approved, for different reasons. Door 1 is sold to the public without a prescription despite the OTC hormone rule. Door 5 is prescribed for an identified patient and prepared by a compounding pharmacy. The fact that neither is FDA-approved does not make them the same category, and it does not make a compounded prescription an OTC product.

"FDA registered," "FDA listed," and "has an NDC" do not mean "FDA approved." FDA's National Drug Code explanation says inclusion in the NDC Directory does not indicate that FDA verified the information or approved the product. Listing is a filing. Approval is a review.

What did the federal labels show for four "OTC estrogen" creams?

*We compared the visible label against the structured strength field in four current DailyMed records submitted as HUMAN OTC DRUG labels. All four were marked unapproved drug other. Three records did not reconcile internally. The fourth—the current Beilloso Women Estriol record—did reconcile.*

Here is how to reproduce the work. DailyMed displays the labeling submitted for a product and structured product information such as the active ingredient, strength, package, route, and marketing category. We opened each current record and read the package language against those structured fields.

The label audit—verified September 1, 2026

Product	Labeler	NDC	Marketing status	What the displayed label says	What the structured strength says	Does it reconcile?
BiEST 5.0 Estrogen Cream	SHYNE BRANDS	82018-0009-3	unapproved drug other	Estriol 0.4% and estradiol 0.1%	Estriol 4 mg in 85 g; estradiol 1 mg in 85 g	No. If the percentages refer to the 85 g container, 0.4% equals 340 mg and 0.1% equals 85 mg—an 85-fold difference from the structured entries
Estriol 5.0 Cream	SHYNE BRANDS	82018-0010-4	unapproved drug other	"Micronizrd Estriol USP (Wild Yam) .5%"	Estriol 5 mg in 85 g	No. If 0.5% refers to the 85 g container, it equals 425 mg—again 85 times the structured entry
Estriol 5000 mcg 5 g	Wise Essentials LLC	87250-105-01	unapproved drug other	The title says 5,000 mcg; another section says "Estriol 5 g 50000 mcg"; the package field describes an 85 g bottle	Estriol 5 g in 5 g, which reads as 100%	No. The same federal record presents three different strength expressions, plus a separate 85 g package amount
Beilloso Women Estriol	Jiangxi Yudexi Pharmaceutical Co., LTD	85248-137-01	unapproved drug other	Micronized estriol 0.1%	Estriol 0.1 g in 100 mL	Yes. Those two expressions are mathematically consistent

That fourth row matters. A serious audit cannot force all four records into the same conclusion. The current Beilloso record reconciles. The finding is three of four, not four of four.

Three more things are visible in the submitted records.

The two SHYNE labels change the standard California warning language. They use the phrase "known only to the state of California." California's familiar warning construction is "known to the State of California." The added word only changes the tone of the warning and appears in the labeler-submitted record.

The Wise Essentials warning names progesterone. The product is labeled as estriol, while the Proposition 65 sentence says it contains progesterone. Progesterone is not listed as an active ingredient in that record. The same record places micronized estriol in an inactive-ingredient section while also listing estriol as the active moiety.

The SHYNE labels combine cosmetic language with drug-use language. The warning says "For external cosmetic use only," while the uses section claims temporary relief from hot flashes. A product can legally be both a cosmetic and a drug when it has both intended uses, but the therapeutic claim still triggers drug requirements. Calling it cosmetic does not erase the drug claim.

Four things this does not mean

We're going to be precise here, because precision is the whole point.

1. DailyMed listing is not FDA approval, endorsement, or verification. The records themselves carry the disclaimer that the drug has not been found by FDA to be safe and effective and that the labeling has not been approved by FDA.
2. These are label-data discrepancies, not laboratory results. We did not assay any jar or pump. We cannot tell which field, if either, reflects the contents.
3. We are not claiming that these products contain too much, too little, or none of the declared hormone. The submitted label and listing do not answer that question reliably.
4. That is the finding. The basic buyer question—how much estrogen does this product deliver?—cannot be established from three of these four federal records.

Check any product yourself in ninety seconds

You do not have to take our word for it. Search the product name on DailyMed and look for:

Marketing status. If it says unapproved drug other, the record is not an FDA approval.
The FDA disclaimer. Read it before treating an NDC or DailyMed page as a quality badge.
Active ingredient / active moiety → strength. Compare the structured amount with the percentage, milligrams, micrograms, pump size, and container size shown elsewhere.
The current version date and labeler. Products can be revised, replaced, or withdrawn.
The arithmetic. One percent of 85 grams is 850 milligrams. One-tenth of one percent is 85 milligrams. One-half of one percent is 425 milligrams.

If the numbers do not reconcile, the label has failed the one job that matters most.

Is there a "strongest" over-the-counter estrogen?

There is no legitimate strongest OTC estrogen in the United States because there is no FDA-approved OTC estrogen category to rank. A larger number, "maximum strength," or a hormone name on an unapproved label does not prove the amount in the product, the amount absorbed, manufacturing quality, or suitability for you.

This is the highest-risk version of the search, so we are going to answer it without building a leaderboard.

The Wise Essentials record says "Estriol Cream 5000 mcg" and directs once- or twice-daily application. If the 5,000-microgram figure were treated as a per-application amount, that would imply 35,000 to 70,000 micrograms of estriol placed on the skin each week. But the same record also says "Estriol 5 g 50000 mcg" and gives a structured strength of 5 g in 5 g. The number cannot be treated as a dependable dose.

For scale only, here are labeled maintenance amounts of estradiol placed with several FDA-approved local products. This is not a potency comparison and not a dosing recommendation.

FDA-approved local product	Labeled maintenance pattern	Estradiol placed per week
Imvexxy 4 mcg vaginal insert	Twice weekly after the initial daily phase	8 mcg
Vagifem/Yuvafem 10 mcg vaginal tablet	Twice weekly after the initial daily phase	20 mcg
Estring 7.5 mcg/day vaginal ring	Continuous release	About 52.5 mcg
Estradiol vaginal cream 0.01%	1 g once weekly	100 mcg
Estradiol vaginal cream 0.01%	1 g twice weekly	200 mcg
Estradiol vaginal cream 0.01%	1 g three times weekly	300 mcg
Estradiol vaginal cream 0.01%, lower labeled initial amount	2 g daily	1,400 mcg
Estradiol vaginal cream 0.01%, upper labeled initial amount	4 g daily	2,800 mcg

Four facts belong beside that table:

Estriol is not estradiol. They are different estrogens and the numbers are not dose-equivalent.
Placed is not absorbed. Skin, vulvar tissue, and vaginal tissue do not produce identical exposure.
The prescription numbers come from defined labels. We are reporting them, not telling anyone what to use.
The unapproved number is internally inconsistent. Treating it as a verified dose would repeat the label's problem instead of solving it.

So here is the honest takeaway:

An unapproved cream is not automatically a gentler version of a prescription. Its own advertised number can be far larger, while the federal record still fails to tell you what the product reliably delivers.

That is why we will not rank these creams by advertised strength. A leaderboard would create certainty the records do not support.

One more word to retire: "bioidentical." In menopause care, the term is often used for hormones with the same chemical structure as hormones made by the body. FDA-approved estradiol products can fit that description. Compounded and unapproved products use the word too. It describes chemistry—not FDA approval, manufacturing quality, evidence, dose accuracy, or clinical fit.

Is estriol estrogen, and does "derived from wild yam" mean natural estrogen?

Estriol is a real human estrogen, and no estriol drug product is FDA-approved in the United States. "Derived from wild yam" describes a manufacturing origin, not an effect of wild yam inside the body. Diosgenin can be converted into steroid hormones in a laboratory; there is no evidence that the human body performs that conversion.

Three endogenous estrogens matter here:

Estrogen	Where it is most prominent	Relative receptor activity	FDA-approved drug products in the U.S.?
Estradiol (E2)	Main estrogen during the reproductive years	Highest of the three in standard comparisons	Yes—multiple prescription products
Estrone (E1)	More prominent after menopause	Lower than estradiol	Present in some approved estrogen products
Estriol (E3)	High during pregnancy; otherwise largely a metabolite	Lower than estradiol	No FDA-approved estriol drug product

The absence of an approved U.S. estriol drug does not make estriol imaginary. It means the American buyer does not have an FDA-approved estriol label, dose, manufacturing file, or indication to compare against an internet cream.

The wild yam story, in three sentences

Chemists learned to use diosgenin from plants such as Mexican yam as a raw material for manufacturing steroid hormones. That conversion is industrial chemistry, requiring processes your body does not perform. Memorial Sloan Kettering's wild yam monograph says there is no evidence the human body converts diosgenin into progesterone.

A placebo-controlled trial of wild yam cream published in Climacteric in 2001 found no significant benefit for menopausal symptoms and no meaningful change in measured hormone levels. The Menopause Society's 2023 review also does not place wild yam among recommended treatments for vasomotor symptoms.

So when a jar says "estriol derived from wild yam," it is telling you about a factory, not a plant acting as estrogen in your body.

The one-second tell

Turn the container over.

If the ingredient information declares estriol or estradiol, a hormone has been added. A no-prescription U.S. product declaring it belongs in Door 1.
If it names only wild yam extract, Dioscorea villosa, or diosgenin with no estrogen drug, it is not estrogen replacement.
If it was prepared by a compounding pharmacy for an identified patient under a prescription, it belongs in Door 5—not Door 1.

For the deeper product-level breakdown, see our wild yam cream for menopause guide.

Which over-the-counter option actually matches your symptom?

Over-the-counter products are not interchangeable. Matching the wrong aisle to the wrong symptom is the most common expensive mistake here: a vaginal moisturizer does not treat hot flashes, a lubricant does not rebuild tissue, and a supplement is not estrogen replacement. Start with the symptom, not the product name.

This is the table we wish existed when we started researching the page.

Your main symptom	What an OTC product can honestly do	What it cannot be treated as	Best next step
Vaginal dryness or day-to-day discomfort	A vaginal moisturizer used on a schedule can add moisture and may improve symptoms	Estrogen replacement or a guaranteed treatment for tissue changes	Try a regular moisturizer if symptoms are mild; if symptoms persist, worsen, or include bleeding, get evaluated
Friction or pain during sex	A lubricant can reduce friction during sex; a moisturizer can improve baseline dryness	A diagnosis or treatment for every cause of pain	Use lubricant now, consider a scheduled moisturizer, and seek evaluation if pain continues
Hot flashes and night sweats	Supplements are sold for these symptoms, but The Menopause Society does not recommend supplements or herbal remedies for vasomotor symptoms	Estrogen replacement	Discuss evidence-based prescription hormonal or nonhormonal options
Sleep broken by night sweats	An OTC sleep product may sedate, but it does not treat the hormonal trigger	Menopause treatment	Treat the night sweats or investigate another sleep problem with a clinician
Recurrent urinary tract infections, urgency, or burning	A moisturizer may help dryness but is not a UTI treatment	An antibiotic, UTI diagnosis, or FDA-approved recurrent-UTI indication	Get evaluated; guidelines recommend vaginal estrogen for some peri- and postmenopausal women with recurrent UTIs, but that is a clinical decision
Bleeding after menopause	Nothing. Do not self-treat this.	A problem to watch at home	Prompt in-person evaluation
Low sexual desire	No OTC product in this article has an FDA-approved indication for low desire	A one-product answer to a multifactorial problem	A clinical conversation that separates pain, dryness, medications, relationship factors, mood, sleep, and hormonal causes
Dry or changing facial skin	Moisturizers and standard dermatology products can help skin-barrier symptoms	A reason to use unapproved hormones on the face	See menopause and dry skin

Notice what happened in that table. The OTC aisle has one defensible job here: moisture and friction relief for vaginal symptoms. Everything else either needs a prescription discussion, a diagnosis, or both.

Not sure which row you are in? Find My HRT Path matches your symptoms, age, uterus status, route preference, insurance, and state to a starting point—and tells you when online care is not the right starting point. It takes about 90 seconds and does not require an email.

Is there anything over the counter that actually helps vaginal dryness?

Yes. A nonhormonal vaginal moisturizer can help some women with vaginal dryness. In a 302-participant randomized trial, a 10-microgram vaginal estradiol tablet and a moisturizer did not outperform their placebo comparison for the primary symptom outcome at 12 weeks; all three groups improved substantially. That supports trying a low-cost moisturizer for mild dryness without pretending it is estrogen.

This is the section that costs us money, and we're leading with it anyway.

The study was Mitchell and colleagues, published in JAMA Internal Medicine in 2018 (PMID 29554173). It included 302 postmenopausal women with moderate-to-severe vulvovaginal symptoms and compared a low-dose vaginal estradiol tablet, a vaginal moisturizer, and double placebo for 12 weeks.

Group	Mean change in most bothersome symptom	95% confidence interval	Versus placebo
Vaginal estradiol 10 mcg	−1.4	−1.6 to −1.2	P = .25
Vaginal moisturizer	−1.2	−1.4 to −1.0	P = .31
Placebo tablet plus placebo gel	−1.3	−1.5 to −1.1	Reference

Sexual-function scores also did not show a significant estradiol-placebo difference in that trial.

Now the fine print, because this result gets misquoted in both directions.

All three groups improved. This was not a "nothing works" trial. The groups did not separate on the primary symptom endpoint.

The placebo arm still used vaginal products. Participants used a placebo tablet and placebo gel. That makes the study practical, but it does not mean the comparison was "do something" versus "do nothing."

It was one 12-week trial, one estradiol dose, and one moisturizer formulation. It does not erase the broader evidence base for low-dose vaginal estrogen, and it does not prove every moisturizer works equally well.

Low-dose vaginal estrogen remains an established treatment for genitourinary syndrome of menopause. The Menopause Society and other professional guidance recognize its effectiveness for vaginal and vulvar symptoms. Separately, the American Urological Association guideline recommends vaginal estrogen to reduce future urinary tract infections in appropriate peri- and postmenopausal women with recurrent UTIs. That recommendation is not the same as saying every vaginal estrogen product has an FDA-approved UTI indication.

So what should you actually do?

If dryness or mild discomfort is the only problem, a vaginal moisturizer used on a schedule is a reasonable first move. Use the product according to its own instructions. A product such as Replens is sold in eight prefilled applicators and says each application may last up to three days.

The difference most people never get told:

Moisturizer—used regularly to improve baseline moisture.
Lubricant—used when friction matters, usually during sexual activity.
Vaginal estrogen—a prescription treatment that acts on estrogen-responsive tissue; it is not interchangeable with either product above.

The 12-week decision rule

Our editorial rule is simple: give a consistent, properly used moisturizer up to 12 weeks if your symptoms are mild and there are no red flags. That matches the duration of the randomized trial; it is not a formal medical guideline.

If you have no meaningful improvement by then, stop cycling through products. Get evaluated for other causes of burning, pain, itching, tearing, or irritation, including infection, dermatologic conditions such as lichen sclerosus, pelvic-floor problems, and other causes that a checkout page cannot see.

Why some moisturizer boxes use vague language

Some vaginal moisturizers are regulated as medical devices rather than drugs. Named products have 510(k) clearances under 21 CFR 884.5300 and product code NUC, where the regulation name is "Condom." That classification history can look bizarre beside a moisturizer, but it reflects the device pathway and predicate structure—not an FDA finding that the product treats every symptom of genitourinary syndrome of menopause.

A 510(k) clearance means FDA found substantial equivalence to a legally marketed predicate device. It is not drug approval, and it is not a blanket clinical-effectiveness endorsement.

What a moisturizer does not do: diagnose recurrent UTIs, evaluate postmenopausal bleeding, reverse every cause of tissue fragility, or replace a prescription when symptoms have moved beyond dryness and friction.

For the prescription side, see our vaginal estrogen guide and where to buy vaginal estrogen online.

Do "natural estrogen" supplements replace estrogen?

No. The Menopause Society's 2023 nonhormone therapy position statement does not recommend supplements or herbal remedies for hot flashes, including soy foods, soy extracts, and S-equol. These products do not provide FDA-approved estrogen replacement. Their labels, mechanisms, evidence, and annual costs vary, so the category name is doing more work than the products deserve.

The Society's 2023 position statement is the cleanest current evidence map for nonhormonal treatment of vasomotor symptoms. We attached dated prices to the categories so you can see what a year of "try this next" can cost.

What you might buy	What it is	The Menopause Society 2023 conclusion for vasomotor symptoms	Important distinction	Dated annual-cost example or range
Black cohosh such as Remifemin	Botanical root extract	Not recommended; evidence did not establish reliable benefit	Rare serious liver-injury reports exist, with causality uncertain	Product-dependent; verify the current label and price
Soy foods or soy isoflavone extracts	Phytoestrogen-containing foods or supplements	Not recommended for treating vasomotor symptoms	Weak receptor activity is not estrogen replacement	Not modeled; products and serving sizes vary
S-equol such as Equelle	A metabolite related to soy isoflavones	Not recommended	Not everyone naturally produces equol from soy; buying it does not change the evidence rating	Not modeled; no dated checkout price was used
Rhapontic rhubarb extract such as Estroven Complete	Standardized botanical extract	Not recommended in the 2023 statement	Estroven Complete is not black cohosh; it is a different ingredient and evidence question	$253.68/year at $18.12 per 28-count box, one daily
Red clover	Isoflavone-containing botanical	Supplements/herbal remedies not recommended	Product composition varies	Not modeled; products and serving sizes vary
Wild yam	Diosgenin-containing botanical	Not an estrogen replacement; no demonstrated human conversion to estrogen	A wild-yam-only product is different from a cream with estriol added	Not modeled; products and serving sizes vary
Oral DHEA	Steroid precursor sold as a supplement	Not established as a menopause treatment in this evidence framework	Not interchangeable with prescription vaginal prasterone	Product-dependent
Mixed "estrogen support" formulas	Multiple botanicals, vitamins, or other ingredients	Cannot be treated as one evidence category	The ingredient panel—not the product name—determines interactions and evidence	Not modeled; no single formula represents the category

That formula distinction matters. The currently priced Estroven Complete Multi-Symptom product uses rhapontic rhubarb extract, while Remifemin is a black-cohosh example. A brand family can contain multiple formulas; the ingredient panel wins.

The black cohosh liver signal—both halves

We are going to give you the whole picture because most pages give you one half.

The National Center for Complementary and Integrative Health reports rare cases of liver damage, some very serious, in people taking commercial black cohosh products, while also stating that it is uncertain whether black cohosh caused them. The NIH LiverTox monograph records clinically apparent acute liver injury linked to products labeled as black cohosh, including severe cases.

So the signal is real, and attribution is genuinely uncertain. Both are true. Anyone taking a black-cohosh product who develops dark urine, jaundice, or significant abdominal symptoms should stop and seek medical care.

For vasomotor symptoms when hormone therapy is not used, the 2023 statement recommends:

cognitive behavioral therapy;
clinical hypnosis;
SSRIs and SNRIs;
gabapentin;
fezolinetant;
oxybutynin;
weight loss; and
stellate ganglion block.

Look at that list. Two are behavioral treatments. Several are prescriptions. Not one is an "estrogen support" bottle. That is why the supplement aisle stays crowded: it lets you feel as though the problem can be solved in a shopping cart.

If hormones are not an option for you, Find My HRT Path routes you toward evidence-based nonhormonal paths and flags when you should be seen in person first. Or read our full guide to nonhormonal menopause options.

What about soy foods?

Eat them if they fit your diet. They are food. Just do not buy soy expecting it to perform the job of prescription estrogen. The 2023 statement did not recommend soy foods, soy extracts, or S-equol for vasomotor symptoms.

Only some people carry gut bacteria that convert the soy compound daidzein into equol. That is one proposed reason studies vary. It is not a reason to turn an inconsistent evidence base into a replacement-hormone claim.

Is over-the-counter DHEA the same as prescription vaginal prasterone?

No. Oral DHEA sold as a supplement and prasterone vaginal inserts are different products, routes, doses, regulatory categories, and evidence bases. Intrarosa is an FDA-approved prescription vaginal insert for moderate-to-severe dyspareunia due to menopausal vulvar and vaginal atrophy. An OTC DHEA capsule is not its substitute.

This catches careful readers because prasterone is another name for DHEA. The molecule name does not erase route, dose, formulation, manufacturing, or approval.

	Oral DHEA supplement	Prasterone vaginal insert (Intrarosa)
Where you get it	Supplement aisle or online	Prescription
Route	Swallowed	Inserted vaginally
FDA status	Dietary supplement; no premarket drug approval	FDA-approved drug
Labeled or marketed purpose	Varies by seller; no FDA-approved menopause indication	Moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause
Evidence transfer	Evidence from another route or product does not automatically apply	Studied and reviewed as the approved vaginal product
Long-term certainty	Depends on product and use; supplement safety is not established through an NDA review	Risks and instructions are addressed in approved prescribing information

FDA approved Intrarosa on November 16, 2016. The evidence for that prescription insert does not turn oral supplement DHEA into a vaginal treatment.

Over-the-counter estrogen cream vs. prescription vaginal estrogen: what is the difference?

Prescription vaginal estrogen provides a defined formulation and strength in an FDA-approved product with approved labeling, pharmacy dispensing, and a prescriber deciding whether it fits. "OTC estrogen cream" can describe a botanical cosmetic, a moisturizer, or an unapproved hormone drug. The product name alone does not tell you which one you are holding.

Six differences actually matter:

Decision point	No-prescription "estrogen cream"	FDA-approved prescription vaginal estrogen
Can you verify the labeled strength?	Not reliably in three of the four current federal records we audited	Yes—the strength and dosage form are defined in approved labeling
Did FDA review effectiveness for the marketed use?	No approved application identified for the audited products	Yes, for the product's approved indication
Is there an approved use?	No FDA-approved indication for the audited products	Product-specific approved indications for menopausal vulvar/vaginal symptoms
Are instructions tied to a studied product?	Often seller-created and sometimes internally inconsistent	Yes; the approved label defines initiation and maintenance instructions
Is a licensed prescriber involved?	No	Yes
Is a pharmacist involved?	Usually no	Yes
Can a no-prescription product be compounded?	Not merely because it says Bi-EST; a compounded product requires a prescription and a compounding pharmacy	Compounded and FDA-approved remain separate paths
What does a year cost?	Depends on what you buy; our reproducible three-product basket was $796.02	Our lower-dose labeled-regimen model for generic cream plus one $34 visit was about $132–$202 in year one

That cost row changes decisions, so it deserves the arithmetic.

What does a year of each route actually cost?

Our dated three-product OTC basket costs $796.02 for one year before tax and shipping. A modeled first year of generic estradiol vaginal cream plus a one-time telehealth visit costs about $132 to $202, using current coupon prices and a lower-dose labeled regimen. The figures are transparent models—not universal quotes—and systemic estrogen is a different calculation.

We modeled both roads. Every assumption is printed so you can replace any input.

Column A—the no-prescription basket

This is not a recommended stack and not an estimate of what every shopper spends. It is a reproducible basket containing one current product from each aisle people commonly combine while searching for "OTC estrogen": a daily menopause supplement, a no-prescription hormone cream, and a scheduled vaginal moisturizer.

What goes in the basket	Price captured September 1, 2026	Published use or package assumption	Units for 365 days	Year-one cost
Estroven Complete Multi-Symptom, 28 count	$18.12 at Walmart	One tablet daily	14 boxes	$253.68
BIOLabs PRO Bi-EST 5.0, 85 g	$54.95 from the seller	About 70 pumps; one pump daily	6 bottles	$329.70
Replens Long-Lasting Vaginal Moisturizer, 8 applications	$13.29 at Target	Up to three days per application; up to 24 days per box	16 boxes	$212.64
Total				$796.02

The number is almost too neat, so check it:

14 × $18.12 = $253.68
6 × $54.95 = $329.70
16 × $13.29 = $212.64
total = $796.02

That basket contains one supplement The Menopause Society does not recommend for vasomotor symptoms, one no-prescription Bi-EST cream whose contents we did not independently test, and one legitimate nonhormonal moisturizer. The moisturizer may still be useful. The fact that the basket is expensive does not make every component useless; it shows how easily three separate problems get sold as one solution.

Column B—the prescription vaginal-estrogen model

Generic estradiol vaginal cream 0.01% comes in a 42.5 g tube. On September 1, 2026:

SingleCare showed $32.51 for one 42.5 g tube at participating pharmacies.
Drugs.com showed a cash-price starting point of $41.88 for 42.5 g.
Sesame advertised general online doctor or prescription visits as low as $34, with the exact provider price displayed before booking. That price floor is not a guaranteed menopause appointment; confirm that the selected clinician and visit type can evaluate your request before paying.

The FDA-approved estradiol cream label includes an initial daily phase, a step-down phase, and maintenance of 1 g one to three times weekly. A tube may last about five months during twice-weekly maintenance, but that maintenance-only shortcut understates first-year use because it leaves out the labeled initial daily phases.

For a transparent lower-dose model, assume:

2 g daily for one week = 14 g;
1 g daily for one week = 7 g;
1 g twice weekly for the remaining 50 weeks = 100 g;
first-year total = 121 g, requiring three 42.5 g tubes.

If the two initial phases last two weeks each, the total becomes:

2 g daily for two weeks = 28 g;
1 g daily for two weeks = 14 g;
1 g twice weekly for the remaining 48 weeks = 96 g;
first-year total = 138 g, requiring four tubes.

Prescription-path input	Low end	High end
Generic estradiol cream	3 × $32.51 = $97.53	4 × $41.88 = $167.52
Illustrative one-time online-doctor price floor	$34	$34
Modeled first-year total	$131.53	$201.52

Rounded for the reader: about $132 to $202 in year one.

Read the two totals again.

The reproducible no-prescription basket costs $796.02. The modeled legal prescription route costs about $132 to $202 for the first year of local vaginal treatment.

Most women expect the opposite. We think we know why: the price they saw was a brand product, a high retail price before a coupon, or a subscription that bundles ongoing care with medication. Drugs.com listed brand-name Estrace Vaginal Cream at $344.68 per 42.5 g tube on the same date—more than eight times its listed generic starting price.

Where this cost comparison stops

The prescription model is not a treatment recommendation and not a promise that a clinician will prescribe estradiol. It assumes a lower labeled cream regimen, a one-time visit available at the displayed floor price, no extra visits, no tax or shipping, and successful use of a coupon or listed cash price. Your prescribed amount may be higher or lower. Insurance may beat the cash price or create different costs.

It also covers local vaginal estrogen. If your primary problem is hot flashes or night sweats, you may need systemic treatment—a patch, pill, gel, or spray—and that has a different price profile and a different risk discussion.

Does the one-visit, local-pharmacy model fit what you are trying to do? See current Sesame visit prices and confirm the appointment type before you book. A clinician decides whether a prescription is appropriate, and the displayed price can vary by clinician, location, and visit type.

How do you get real estrogen online without waiting months?

You can use a one-time cash-pay telehealth visit, an ongoing cash-pay menopause subscription, an insurance-billing menopause clinic, or a bundled direct-to-consumer program. The cheapest shape depends on whether you need only one evaluation or ongoing dose changes, whether insurance applies, and whether you want medication sent to your pharmacy or shipped by the program.

Before the table, the disclosure: we may earn a commission from Sesame, Midi Health, and Hers. We do not earn a commission from the generic estradiol cream priced above, from the moisturizer trial, or from telling you to see someone in person.

And here is the part that should tell you more than any badge: we left Winona and Inner Balance/Oestra off this page on purpose. They are affiliate partners we could have linked to, but their lead paths use compounded hormones. This page's decision is about getting a measurable, FDA-approved estrogen prescription. Sending you from the label audit straight to a compounded-cream subscription would contradict the evidence above.

Verified provider routes—September 2026

Route	Published price	What is included	Where medication goes	Best for	Watch out for
Sesame one-time online-doctor visit	General online-doctor or prescription-visit prices advertised as low as $34	One video visit; no menopause-subscription benefits are implied	Preferred local pharmacy if prescribed	Cash-pay reader who finds a clinician and visit type that explicitly fit the request	The $34 floor is not a guaranteed menopause appointment; confirm the visit type before paying. Additional follow-up is separate
Sesame menopause subscription	From $59/month	Provider choice, video visits as needed, unlimited messaging, treatment adjustments, and basic labs if the provider orders them	Local pharmacy; medication cost is separate	Cash-pay reader who wants ongoing support without insurance billing	First month is nonrefundable after the initial visit; cancel before the next billing cycle. Lab-payment exceptions apply in NY, NJ, RI, and ND
Midi Health	Self-pay $250 initial / $150 continued-care visit; in-network with most PPO plans	Menopause-focused visits, ongoing dose or route changes, and insurance billing where applicable	Prescription generally goes through the patient's pharmacy/plan	Commercial PPO coverage or a reader who wants clinician-led follow-up	Coverage varies by plan. Midi cannot treat Medicaid or Medi-Cal patients even as self-pay. Medicare beneficiaries may self-pay, but Midi is not covered by Medicare and claims cannot be submitted
Hers menopause care	Published anchors: oral medication from $79/month and patches from $134/month on 12-month plans	Online intake, licensed-provider review, personalized treatment if prescribed, medication delivery, unlimited provider messaging, check-ins, and adjustments	Program pharmacy/delivery	Cash-pay reader who wants assessment, medication, and ongoing support in one system	Not available in all 50 states. Hers does not publish a standalone vaginal-cream price on the reviewed page. Plans auto-renew unless canceled at least two days before renewal

Sesame has two different shapes

Sesame is not one care model. Its one-time appointment and its menopause subscription solve different problems.

A one-time Sesame appointment does not include the ongoing menopause program. If you want continuing messages, basic labs when ordered, and video visits as needed, the $59/month menopause subscription is the relevant Sesame path. Midi and Hers also offer ongoing care.

The damaging admission belongs to the one-time visit, not the subscription:

Sesame's one-time visit does not manage you over time. If ongoing follow-up is your priority, the Sesame menopause subscription, Midi, or Hers is a better shape. But stripping out the ongoing layer is exactly why a one-off appointment can be the lowest-cost entry.

That is not a flaw for the woman who wants one evaluation and her own pharmacy. It is a real flaw for the woman whose first three months are likely to involve dose, route, or frequency changes.

If one visit and your own pharmacy are what you want, check current one-time Sesame prices and availability.

If you want ongoing cash-pay care without insurance

Sesame's menopause subscription currently starts at $59 a month. Its page says the program includes video visits as needed, unlimited messaging, medication adjustments, and basic labs if the provider orders them. Medication is priced separately.

The lab detail matters. Sesame says most orders go to Quest; Arizona, Oklahoma, South Dakota, and Wisconsin use Labcorp; Hawaii uses Clinical Labs of Hawaii. Patients in New York, New Jersey, and Rhode Island pay Quest directly, and patients in North Dakota pay the lab directly.

The cancellation detail matters too. Sesame says a subscriber who cancels at least three hours before the initial visit receives a full refund. After the initial visit, the first month is not refundable. The subscription can be canceled before the next billing cycle to stop future charges; prior months are not refundable.

If $59/month for follow-up, messaging, and provider-ordered basic labs fits better than paying visit by visit, see Sesame's current menopause-program details.

If you have commercial PPO insurance

Midi Health publishes self-pay prices of $250 for the initial visit and $150 for continued-care visits, while stating that it is in-network with most PPO plans. Coverage still depends on the actual plan, deductible, coinsurance, copay, and service.

The exclusion is material:

Midi says it cannot treat Medicaid or Medi-Cal patients at this time, even as self-pay.
Midi is not covered by Medicare or Medicare-related plans.
Medicare beneficiaries may use Midi as self-pay patients, but Midi says claims for its visits, medications, or associated services cannot be submitted.

For a commercially insured reader, the upside is the opposite of a bundled seller: the clinical visit and prescription can run through insurance and the medication can be selected against the plan's formulary.

A company-published service quote describes that route this way:

"Midi was incredibly easy. I signed up and had a visit the next day. My clinician was kind and thoughtful." — Katherine G., published by Midi Health

That is one person's company-published service experience. It is not a typical result and not evidence that any treatment works.

If you have a commercial PPO, verify your exact network status before paying cash: check Midi coverage and availability.

If you want one assessment, medication delivery, and ongoing messaging

Hers says its menopause program may include an estradiol pill or patch, progesterone when appropriate, and estradiol vaginal cream. A licensed provider reviews the intake and decides whether treatment is appropriate. The program includes unlimited provider messaging, regular check-ins, and treatment adjustments.

Hers publishes oral-medication pricing from $79 a month and patch pricing from $134 a month on 12-month plans. It does not publish a standalone price for vaginal cream on the reviewed menopause page, so do not assume the cream costs either anchor. Confirm the exact medication, quantity, billing cadence, and total during the assessment and checkout.

Hers is cash-pay and says its menopause care is not available in all 50 states. Its terms state that subscriptions automatically renew unless canceled at least two days before the renewal processing date.

If one system for intake, shipped medication, messaging, and adjustments fits your life better, start the Hers eligibility assessment. Completing the assessment does not guarantee a prescription.

Still deciding which route you are?

Use Find My HRT Path. It asks about symptoms, age, uterus status, route preference, insurance, and state, then routes you toward the right provider model—or tells you when online care is not the right starting point.

Who these online routes do not work for

An online visit cannot examine tissue, palpate a mass, test a discharge on the spot, or see every condition that can look like menopause. Lichen sclerosus, infection, vulvodynia, pelvic-floor problems, and other conditions can overlap with dryness, burning, and pain.

If you have bleeding after menopause, a new lump or sore, unexplained pelvic pain, or another finding that needs an examination, start in person.

Why can a UK pharmacy sell vaginal estrogen when a U.S. store cannot?

Because the countries classify access differently. The UK's regulator reclassified Gina 10-microgram vaginal estradiol tablets from prescription-only to a pharmacy medicine for eligible postmenopausal women aged 50 or older, after pharmacist screening. Boots listed 24 tablets at £29.99. That UK status does not make Gina an OTC U.S. drug or legal to import routinely.

This comes up constantly because women read about Gina and reasonably ask why the same route is not available here.

Three things matter.

It is pharmacy-gated, not an unrestricted shelf product. The MHRA reclassification applies to women aged 50 and over who have not had a period for at least one year. Supply follows consultation with a pharmacist using training materials and a checklist.

It is local estrogen. Gina treats postmenopausal vaginal symptoms. It is not a nonprescription systemic patch or pill for hot flashes.

The classification does not cross the Atlantic. FDA says that, in most circumstances, individuals may not import drugs that are unapproved in the United States. FDA has limited personal-importation discretion for specific situations, but it is not a general online-shopping permission slip.

The useful takeaway is not envy. A working nonprescription model exists—and it looks like a healthcare-professional gate, not a seller shipping hormones to anyone with a credit card.

Is estrogen about to become available over the counter in the U.S.?

Not yet. FDA changed boxed-warning language for six menopausal hormone-therapy products in February 2026 and held a broad public meeting on expanding nonprescription drug access in April. As of September 1, 2026, no estrogen appears on FDA's prescription-to-nonprescription switch list. No FDA approval date for nonprescription vaginal estrogen has been published.

This is the fastest-moving part of the page, so here is the official timeline without turning intentions into approvals.

Date	What happened	What changed for the buyer
November 10, 2025	FDA requested menopausal hormone-therapy labeling changes	Began a warning-label process; access did not change
February 12, 2026	FDA approved revised labeling for Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva	Certain risk statements were removed from the boxed warning; all six remained prescription-only
April 23, 2026	FDA held the public meeting Increasing Access to Nonprescription Drugs	Opened a broad policy discussion; it did not approve an estrogen product
September 1, 2026	FDA's switch list contains no estrogen product	A U.S. prescription is still required for FDA-approved estrogen

How to check this yourself in thirty seconds

FDA maintains a public Prescription to Nonprescription Switch List. Search the current table for estradiol, estrogen, and any named product.

The list covers formal prescription-to-nonprescription switches, while other nonprescription application pathways also exist. For the practical question on this page, the conclusion is the same: no FDA-approved estrogen medicine is currently sold without a prescription in the United States.

Announcements are not approvals. Meetings are not approvals. Label changes are not access changes.

What should you check before paying for any estrogen product online?

Before paying for a no-prescription product marketed with estrogen language, check the ingredient panel, current DailyMed marketing status, internal dose arithmetic, labeler and revision date, and whether a licensed clinician screens you before access. "FDA registered," "NDC listed," "GMP," and "natural" are not substitutes for FDA drug approval.

This checklist takes about five minutes.

1. Read the ingredient panel, not the front

Does the product declare estriol or estradiol? Then it claims to contain a hormone. Does it list only wild yam, soy, black cohosh, rhubarb, or another botanical? Then it is not estrogen replacement.

2. Search the exact product on DailyMed

Confirm the spelling, labeler, NDC, package size, route, and revision date. Marketplace listings and seller pages can outlive the federal record they once pointed to.

3. Read the marketing status and disclaimer

Unapproved drug other is not a gray version of approval. It means the record is not an approved application. An NDC is an identifier, not an FDA quality seal.

4. Do the percentage math

Convert the percentage into an amount against the stated package or dose. Then compare it with the structured strength.

1% of 85 g = 850 mg
0.5% of 85 g = 425 mg
0.1% of 85 g = 85 mg
0.1 g in 100 mL = 0.1%

If two fields disagree by a factor of 85, you do not have a dose—you have a documentation failure.

5. Ask what the seller knows about you

A legitimate prescription route asks about symptoms, age, menstrual status, uterus status where relevant, unexplained bleeding, cancer and clotting history, medications, and other clinical factors. A retail checkout that asks only for a shipping address is not performing that screen.

6. Separate facility language from product approval

"Made in an FDA-inspected facility," "GMP," "USP ingredient," and "FDA registered" may describe a facility, ingredient standard, or filing. None means FDA approved the finished product for your use.

7. Be careful with overseas sellers

FDA says imported foreign drugs are generally unapproved in the United States even when legal elsewhere, and routine personal importation is generally illegal. Products outside the legitimate U.S. supply chain do not carry the same assurance of identity, storage, quality, or authenticity.

We will not name sellers or map import routes. Once shipping and risk are counted, a legitimate one-time telehealth visit can cost less and produce a prescription a U.S. pharmacy can fill.

Do you need progesterone if you use an estrogen cream yourself?

If you have a uterus and absorb meaningful systemic estrogen, unopposed estrogen can stimulate the endometrium, which is why a progestogen is generally used with systemic estrogen. Low-dose local vaginal estrogen is treated differently in major guidance and usually does not require routine added progestogen. An unapproved skin cream with an uncertain dose does not automatically qualify for that exception.

Follow the logic because it is short and it matters.

A progestogen—progesterone or another progestogenic medicine—reduces the risk of endometrial hyperplasia associated with systemic estrogen in a person with a uterus. That is why uterus status changes the standard systemic-hormone conversation.

The local-vaginal exception is real. Major menopause guidance generally does not require routine added progestogen with low-dose vaginal estrogen. That conclusion depends on a defined product, route, and low dose.

A no-prescription cream applied to the arms, thighs, or chest is not local vaginal therapy. When the label and structured listing do not reconcile, you also cannot establish that the exposure is "low" from the record.

If you have been using one of these creams and have a uterus, bring the container or clear label photos to a clinician. Do not add an OTC progesterone cream on your own to "balance it." Adding a second hormone does not repair uncertainty in the first product.

And one hard line, with no soft edges: bleeding after menopause needs prompt evaluation. The American College of Obstetricians and Gynecologists' updated 2026 guidance addresses evaluation pathways because the cause has to be identified; this is not a symptom to cover with another cream.

More detail: Do you need progesterone with vaginal estrogen?

When should you skip over-the-counter products and get seen in person?

Some situations need an examination before any hormone product. Bleeding after menopause, unexplained pelvic pain, a new vulvar or vaginal sore or lump, and symptoms that persist despite consistent nonhormonal care all need a cause—not another checkout. Cancer history, clotting history, liver disease, and certain medications also require individualized clinical judgment.

We'd rather lose you here than be wrong about you.

Your situation	Why it changes the answer	Better starting point
Any bleeding after menopause	The cause must be identified before self-treatment	Prompt in-person evaluation
New vulvar or vaginal lump, sore, ulcer, or skin change	Needs direct examination	Gynecology, primary care, or another in-person clinician
Unexplained pelvic pain	Online intake cannot examine the abdomen or pelvis	In-person clinician
Possible UTI, fever, flank pain, or blood in urine	May need urine testing and treatment	Prompt clinical evaluation
Personal history of breast, uterine, or ovarian cancer	Hormone decisions require cancer-specific context	The clinician or oncology team managing that history
Taking tamoxifen or an aromatase inhibitor	Vaginal-symptom treatment requires coordination and shared decision-making	Oncology team plus the appropriate women's-health clinician
Prior clot, stroke, or known clotting disorder	Route, dose, indication, and alternatives matter	Clinician who can review the full history
Active or significant liver disease	Hormone metabolism and product choice require individual assessment	In-person or established treating clinician
No meaningful improvement after up to 12 weeks of consistent moisturizer use	Another condition or stronger treatment may be needed	Vulvar/vaginal examination
Menopause-type symptoms before age 45	Early menopause and primary ovarian insufficiency have different diagnostic and long-term implications	Clinician rather than a retail product

If you are in one of those rows, close the shopping tab and make the appointment. Find My HRT Path will tell you the same thing: flagging when online care is not the right starting point is one of the things it is built to do.

How did The HRT Index verify this page?

This is editorial research, not medical advice, and it has not been reviewed by a clinician. Every major claim traces to a named source and date. We compared federal label fields ourselves, rebuilt the cost model from current retail inputs, separated provider-stated facts from our arithmetic, and removed any claim we could not verify.

This page was built under The HRT Index Verification Standard—our documented process for reviewing providers and products: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule, with top providers checked monthly and the full roster quarterly.

We evaluate providers on five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, and access. We do not publish invented numeric scores for providers or products.

What we did for this page

Read 21 CFR 310.530 in full.
Opened four current DailyMed records and compared visible label statements with structured active-ingredient strengths.
Opened the current Beilloso Women Estriol record rather than carrying forward an older NDC, then reported the result that record supports.
Checked FDA's current switch list and 2025–2026 hormone-label actions.
Read the 302-participant randomized trial rather than relying on an article about it.
Read The Menopause Society's full 2023 position statement.
Checked FDA, MHRA, and provider pages for access, import, price, insurance, lab, and cancellation terms.
Captured retail prices from named sellers and showed every annualization assumption.
Built the prescription cost model around the labeled initial and maintenance phases rather than annualizing maintenance use alone.

Provider-stated facts versus our calculations

Type of information	Provider or source stated	The HRT Index calculated or concluded
BIOLabs price and about 70 pumps	$54.95; about 70 pumps; one pump daily	Six bottles/year = $329.70
Estroven price and count	$18.12; 28-count	Fourteen boxes/year = $253.68
Replens price and package duration	$13.29; eight applications; up to 24 days	Sixteen boxes/year = $212.64
Generic estradiol prices	$32.51 and $41.88 per 42.5 g tube	Three to four tubes in the transparent lower-dose model
Sesame one-time visit	As low as $34	Added once to the medication model
OTC basket	No seller publishes this basket total	$796.02/year
Prescription model	No provider promises this annual total	$131.53–$201.52/year under the stated assumptions

What we still cannot tell you

We cannot tell you what is actually inside the four unapproved creams without independent laboratory testing. We cannot promise a prescription, dose, coupon price, insurance payment, appointment price, or medication fit. We cannot predict whether FDA will approve nonprescription vaginal estrogen.

Where the evidence stops, the sentence stops.

How we handle money

We may earn a commission from Sesame, Midi Health, and Hers. We do not earn one from the moisturizer trial, the current generic-price listings, or the recommendation to seek in-person care. We excluded two affiliate partners whose lead compounded paths did not fit this page's FDA-approved-estrogen decision.

Corrections and recency

The DailyMed records, FDA access status, retail prices, and provider terms can change. This page should be checked monthly for FDA switch status and provider pricing, quarterly for DailyMed records and retail inputs, and immediately after a material FDA action.

When the evidence changes, the visible Last verified date should change with it—not before.

Frequently asked questions

Is there an over the counter estrogen replacement that actually contains estrogen?

Some no-prescription creams declare estriol or estradiol on their labels. That does not make them FDA-approved OTC estrogen. All four federal records we examined were marked unapproved drug other, and three of the four had strength information that did not reconcile internally. A hormone may be declared, but the record does not reliably establish the delivered amount.

What is the strongest over-the-counter estrogen cream?

There is no legitimate ranking. No FDA-approved OTC estrogen category exists in the United States, and an advertised milligram or microgram number on an unapproved product does not prove content, absorption, quality, or clinical strength.

Is estriol cream FDA-approved?

No estriol drug product is FDA-approved in the United States. Estriol can appear in unapproved no-prescription products or in compounded prescription preparations. Those are distinct categories, and neither should be represented as an FDA-approved estriol medicine.

Can you buy estrogen pills over the counter?

No FDA-approved oral estrogen medicine is sold over the counter in the United States. Products in the supplement aisle with names such as "estrogen support" are dietary supplements, not estrogen drugs.

Does black cohosh work for hot flashes?

The Menopause Society's 2023 position statement does not recommend supplements or herbal remedies, including black cohosh, for vasomotor symptoms. NIH sources also record rare serious liver-injury reports involving products labeled as black cohosh, while noting uncertainty about causality.

What is the best over-the-counter product for vaginal dryness?

A nonhormonal vaginal moisturizer used consistently is the strongest OTC starting point for mild dryness. A lubricant can reduce friction during sex. If symptoms persist, involve tearing or bleeding, or include urinary problems, get evaluated rather than buying another product.

Can you use an over-the-counter estrogen cream on your face?

No menopause hormone product has an FDA-approved indication for facial appearance, and the federal OTC hormone rule still applies. For the skin question rather than the hormone-access question, see menopause and dry skin.

Do you need progesterone with an over-the-counter estrogen cream?

That cannot be answered safely from the product name. The usual no-routine-progestogen exception applies to defined low-dose local vaginal estrogen. An unapproved skin cream with a dose that cannot be verified from its record is not automatically in that category. A clinician should review what you used, your uterus status, and any bleeding.

How much does prescription estrogen cost without insurance?

For generic estradiol vaginal cream 0.01%, current pages showed $32.51 with a SingleCare card at participating pharmacies and a Drugs.com cash-price starting point of $41.88 for 42.5 g. Your pharmacy, ZIP code, coupon, prescribed quantity, and insurance can change the number. Systemic pills, patches, gels, and sprays price differently.

Can you get an estrogen prescription online without an in-person visit?

Often, yes, when telehealth is legally available in your state and a licensed provider determines that treatment is appropriate. Some services use video visits; some treatment paths include ongoing care. Online care cannot physically examine you, so certain symptoms still belong in person.

Is vaginal estrogen going over the counter in 2026?

It has not happened as of September 1, 2026. FDA changed warning language for six prescription hormone products and held a broad nonprescription-access meeting, but no estrogen product appears on the prescription-to-nonprescription switch list.

Can you buy Gina vaginal estradiol tablets in the U.S.?

Gina is a UK pharmacy medicine for eligible postmenopausal women after pharmacist screening. That UK classification does not make it an approved U.S. nonprescription drug. FDA says routine personal importation of unapproved foreign drugs is generally illegal, subject to narrow enforcement-discretion criteria.

Are compounded "bioidentical" creams the same as over-the-counter creams?

No. A compounded hormone is prepared under a prescription for an identified patient by a compounding pharmacy. A no-prescription cream is sold directly to the public. Neither is FDA-approved, but the legal paths and controls are different. Do not treat them as equivalent.

I already used an over-the-counter estrogen cream. What should I do?

Do not panic and do not assume harm. Keep the container, take clear photos of every panel, and tell a clinician what you used, where you applied it, how much, and for how long. If you have had bleeding after menopause, unexplained pelvic pain, or another red-flag symptom, get evaluated promptly.

The bottom line on over the counter estrogen replacement

No FDA-approved estrogen is sold over the counter in the United States. Products marketed that way are usually unapproved hormone drugs, supplements that are not estrogen replacement, or nonhormonal products for moisture and friction. A moisturizer has a real role for mild vaginal dryness. For estrogen itself, a prescription creates the measurable product and accountable clinical path the OTC aisle cannot provide.

If we could leave you with four sentences:

1. The word on the front is not the category. The ingredient panel, marketing status, approval status, route, and prescription requirement decide what you are holding.
2. Match the product to the symptom. A moisturizer can be a good first answer for dryness and a useless answer for hot flashes.
3. The legal route can be cheaper. Our reproducible OTC basket was $796.02; the transparent first-year generic vaginal-estrogen model was about $132 to $202.
4. You are allowed to want this. Nothing on this page is a reason to keep suffering. It is a reason to spend your money where the dose is defined and someone is accountable.

Still not sure which HRT program is right for you? Take our free 90-second matching quiz: Find My HRT Path. It asks about your symptoms, age and uterus status, route preference, insurance, and state, then points you toward the right starting point—including telling you when online care is not it. No email needed.

Sources

Regulatory and product records

21 CFR 310.530—Topically applied hormone-containing drug products for OTC human use
FDA Prescription to Nonprescription Switch List
FDA National Drug Code Directory
FDA: Unapproved Drugs
FDA: Compounding and the FDA—Questions and Answers
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026
FDA Public Meeting on Increasing Access to Nonprescription Drugs, April 23, 2026
DailyMed: BiEST 5.0 Estrogen Cream, NDC 82018-0009-3
DailyMed: Estriol 5.0 Cream, NDC 82018-0010-4
DailyMed: Estriol 5000 mcg 5 g, NDC 87250-105-01
DailyMed: Beilloso Women Estriol, NDC 85248-137-01
FDA Personal Importation
MHRA: Gina 10-microgram vaginal tablets reclassification
Boots: Gina 10-microgram vaginal tablets, 24 count—£29.99, captured September 1, 2026
FDA 510(k) records reviewed for vaginal moisturizers: K101098 and K101241 (Replens), K213220 (Revaree Plus), and K152507 (Vagisan), through the FDA 510(k) Premarket Notification database
21 CFR 884.5300—Condom, the device regulation cited in the reviewed clearance records
FDA-approved product labels reviewed for dose comparisons: estradiol vaginal cream 0.01%, Imvexxy, Yuvafem/Vagifem, and Estring

Clinical evidence

Mitchell CM, Reed SD, Diem S, et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms. JAMA Internal Medicine. 2018;178(5):681–690.
The Menopause Society. The 2022 hormone therapy position statement
The Menopause Society. The 2023 nonhormone therapy position statement. Menopause. 2023;30(6):573–590.
American Urological Association. Recurrent Uncomplicated Urinary Tract Infections in Women Guideline
American College of Obstetricians and Gynecologists. Updated guidance on evaluating postmenopausal bleeding
National Center for Complementary and Integrative Health. Menopausal Symptoms: In Depth
LiverTox. Black Cohosh
Memorial Sloan Kettering Cancer Center. Wild Yam
Komesaroff PA, et al. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric. 2001;4(2):144–150.
FDA Drugs@FDA. Intrarosa approval package

Price and provider snapshots

BIOLabs PRO Bi-EST 5.0—$54.95 and about 70 pumps, captured September 1, 2026
Walmart Estroven listings—Estroven Complete 28 count at $18.12, captured September 1, 2026
Target Replens Long-Lasting Vaginal Moisturizer—eight applications at $13.29, captured September 1, 2026
SingleCare estradiol prices—$32.51 for 42.5 g at participating pharmacies, captured September 1, 2026
Drugs.com estradiol topical prices—$41.88 starting cash price for 42.5 g, captured September 1, 2026
Sesame online prescription and doctor visits—general online-doctor visits advertised from $34; a new prescription may be written when a provider decides it is appropriate, captured September 1, 2026
Sesame menopause treatment—from $59/month, features, lab exceptions, and refund terms, captured September 1, 2026
Midi Health HRT pricing and coverage—$250 initial and $150 continued self-pay; PPO, Medicaid, and Medicare terms, captured September 1, 2026
Hers menopause program—medication options, eligibility, availability, and ongoing support, captured September 1, 2026
Hers HRT cost article—$79 oral and $134 patch anchors on 12-month plans, captured September 1, 2026
Hers terms and conditions—auto-renewal and cancellation terms, captured September 1, 2026

Educational only. Not medical advice or a substitute for care from a licensed clinician who knows your history.

Keep the symptom, route, and evidence connected.

Compare the vaginal estrogen guide, review nonhormonal options, read the FDA-approved HRT medication list, or use Find My HRT Path before choosing a product or changing prescribed care.

Keep reading: